About Nanoligent
Nanoligent is a company based in Barcelona (Spain) founded in 2017 by M Rodriguez, Ramon Mangues, Antonio Villaverde, and Esther Vazquez.. Nanoligent has raised $15.05 million across 3 funding rounds from investors including i&i Bio, Italian Angels for Growth and AVANTECA. Nanoligent offers products and services including Targeted Protein Conjugates and Drug Development Platform. Nanoligent operates in a competitive market with competitors including Certis Oncology Solutions, Xentech and Rincon Bio, among others.
- Headquarter Barcelona, Spain
- Founders M Rodriguez, Ramon Mangues, Antonio Villaverde, Esther Vazquez
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Nanoligent S.L.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$15.05 M (USD)
in 3 rounds
-
Latest Funding Round
$13.92 M (USD), Series A
Oct 10, 2025
-
Investors
i&i Bio
& 3 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Nanoligent
Nanoligent offers a comprehensive portfolio of products and services, including Targeted Protein Conjugates and Drug Development Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Engineers nanoparticles for precise cancer drug delivery and targeting
Designs new precision medicines for oncology and other diseases
Unlock access to complete
Unlock access to complete
Funding Insights of Nanoligent
Nanoligent has successfully raised a total of $15.05M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $13.92 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series A — $13.9M
-
First Round
First Round
(03 Feb 2022)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2025 | Amount | Series A - Nanoligent | Valuation |
investors |
|
| Sep, 2022 | Amount | Seed - Nanoligent | Valuation |
investors |
|
| Feb, 2022 | Amount | Seed - Nanoligent | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Nanoligent
Nanoligent has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include i&i Bio, Italian Angels for Growth and AVANTECA. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
A network of business angels is formed to support innovative startups.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Nanoligent
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Nanoligent
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Nanoligent Comparisons
Competitors of Nanoligent
Nanoligent operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Certis Oncology Solutions, Xentech and Rincon Bio, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Oncology-based in-vivo drug development services are provided.
|
|
| domain | founded_year | HQ Location |
Patient-derived xenograft models for preclinical oncology research are provided.
|
|
| domain | founded_year | HQ Location |
Pre-clinical CRO for in vivo cancer efficacy studies using xenograft and syngeneic models.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Nanoligent
When was Nanoligent founded?
Nanoligent was founded in 2017 and raised its 1st funding round 5 years after it was founded.
Where is Nanoligent located?
Nanoligent is headquartered in Barcelona, Spain. It is registered at Barcelona, Catalonia, Spain.
Who is the current CEO of Nanoligent?
Montserrat Cano Biosca is the current CEO of Nanoligent.
Is Nanoligent a funded company?
Nanoligent is a funded company, having raised a total of $15.05M across 3 funding rounds to date. The company's 1st funding round was a Seed of $1.13M, raised on Feb 03, 2022.
What does Nanoligent do?
Nanoligent was founded in 2017 and is based in Barcelona, Spain. Preclinical services focused on oncology drug development are offered, supporting research and testing phases for pharmaceutical clients. Operations center on biological and pharmacological evaluations, including in vitro and in vivo models. Expertise in nanotechnology applications is utilized to advance therapeutic candidates in the biotech sector. Leadership includes co-founders with backgrounds in oncology and molecular biology.
Who are the top competitors of Nanoligent?
Nanoligent's top competitors include Certis Oncology Solutions, Xentech and Rincon Bio.
What products or services does Nanoligent offer?
Nanoligent offers Targeted Protein Conjugates and Drug Development Platform.
Who are Nanoligent's investors?
Nanoligent has 4 investors. Key investors include i&i Bio, Italian Angels for Growth, AVANTECA, and Inveready.